Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.03
EGLT's Cash-to-Debt is ranked lower than
81% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. EGLT: 1.03 )
Ranked among companies with meaningful Cash-to-Debt only.
EGLT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.82 Max: No Debt
Current: 1.03
Equity-to-Asset 0.05
EGLT's Equity-to-Asset is ranked lower than
91% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. EGLT: 0.05 )
Ranked among companies with meaningful Equity-to-Asset only.
EGLT' s Equity-to-Asset Range Over the Past 10 Years
Min: -3.39  Med: 0.05 Max: 0.73
Current: 0.05
-3.39
0.73
Piotroski F-Score: 2
Altman Z-Score: -3.75
Beneish M-Score: 0.61
WACC vs ROIC
3.49%
-2046.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -477.62
EGLT's Operating Margin % is ranked lower than
70% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. EGLT: -477.62 )
Ranked among companies with meaningful Operating Margin % only.
EGLT' s Operating Margin % Range Over the Past 10 Years
Min: -1934.17  Med: -477.62 Max: -228.72
Current: -477.62
-1934.17
-228.72
Net Margin % -534.26
EGLT's Net Margin % is ranked lower than
72% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. EGLT: -534.26 )
Ranked among companies with meaningful Net Margin % only.
EGLT' s Net Margin % Range Over the Past 10 Years
Min: -2250.73  Med: -534.26 Max: -253.76
Current: -534.26
-2250.73
-253.76
ROE % -186.26
EGLT's ROE % is ranked lower than
89% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. EGLT: -186.26 )
Ranked among companies with meaningful ROE % only.
EGLT' s ROE % Range Over the Past 10 Years
Min: -444.79  Med: -191.72 Max: -86.8
Current: -186.26
-444.79
-86.8
ROA % -63.81
EGLT's ROA % is ranked lower than
75% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. EGLT: -63.81 )
Ranked among companies with meaningful ROA % only.
EGLT' s ROA % Range Over the Past 10 Years
Min: -307.77  Med: -123.58 Max: -49.73
Current: -63.81
-307.77
-49.73
ROC (Joel Greenblatt) % -702.45
EGLT's ROC (Joel Greenblatt) % is ranked lower than
57% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. EGLT: -702.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
EGLT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1093.04  Med: -822.41 Max: -672.52
Current: -702.45
-1093.04
-672.52
3-Year EBITDA Growth Rate 61.60
EGLT's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. EGLT: 61.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
EGLT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -13.2 Max: 61.6
Current: 61.6
0
61.6
3-Year EPS without NRI Growth Rate -38.20
EGLT's 3-Year EPS without NRI Growth Rate is ranked lower than
84% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. EGLT: -38.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
EGLT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -38.2 Max: -11.1
Current: -38.2
GuruFocus has detected 5 Warning Signs with Egalet Corp $EGLT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» EGLT's 10-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

EGLT Guru Trades in Q2 2015

Jim Simons 36,400 sh (New)
» More
Q3 2015

EGLT Guru Trades in Q3 2015

Jim Simons 31,800 sh (-12.64%)
» More
Q4 2015

EGLT Guru Trades in Q4 2015

Jim Simons 47,300 sh (+48.74%)
» More
Q1 2016

EGLT Guru Trades in Q1 2016

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with EGLT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:AMEX:XXII, NAS:ECYT, NAS:BDSI, OTCPK:IMMVF, OTCPK:NURPF, OTCPK:ORGS, NAS:GEMP, NAS:CDXC, NAS:NOVN, NAS:PIRS, NAS:AFMD, NAS:CTRV, NAS:AGLE, NAS:ADVM, OTCPK:MCUJF, OTCPK:TBGNF, NAS:PRQR, NAS:CRME, NAS:EIGR, NAS:VVUS » details
Traded in other countries:EGP.Germany,
Headquarter Location:USA
Egalet Corp is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize proprietary, abuse-deterrent oral products for the treatment of pain and in other indications.

Egalet Corp is a specialty biopharmaceutical company involved in the development and commercialization of pain treatments. Using its proprietary Guardian Technology, the company developed an extended-release morphine product, ARYMO ER, within the therapeutic area of severe pain management. Moreover, Egalet markets two novel pain products: SPRIX (ketorolac tromethamine) nasal spray, and OXAYDO (oxycodone HCl, USP) tablets for oral use.

Top Ranked Articles about Egalet Corp

DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet Corporation (EGLT) & Lead Plaintiff Deadline - March 28, 2017

NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Egalet Corporation (“Egalet” or the “Company”) (NASDAQ:EGLT) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Egalet securities between December 15, 2015, and January 9, 2017, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/eglt. The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). The Complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose material adverse information about its lead product, ARYMO ER and the likelihood that it would receive oral abuse-deterrent labeling. On January 9, 2017, Egalet released a statement announcing the approval of its product Arymo ER. Later that day, the U.S. Federal Drug Administration stated that a competitor product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Following this news, Egalet stock dropped, thus damaging investors. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/eglt or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Egalet you have until March 28, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Egalet Corporation and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, March 24, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Egalet Corporation (“Egalet” or the “Company”) (NASDAQ:EGLT). Investors who purchased or otherwise acquired Egalet shares between December 15, 2015 and January 9, 2017 inclusive (the “Class Period”), are encouraged to contact the firm in advance of the March 28, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected]. No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member. The investigation is centered on whether Egalet and some of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On January 9, 2017, Egalet issued a statement regarding approval for its product Arymo ER. The same day, the U.S. Federal Drug Administration stated that another product MorphaBond “has marketing exclusivity for labeling describing the expected reduction of abuse of single-entity extended-release morphine by the intranasal route due to physicochemical properties.” Due to MorphaBond’s exclusivity within this market, “no other single-entity extended-release morphine product submitted in an abbreviated new drug application or 505(b)(2) application can be approved for that use at this time.” When this information was revealed to the investing public, the value of Egalet declined, causing investors severe harm. Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contact:

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
[email protected]
http://lundinlawpc.com/

Read more...
EGLT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Egalet Corporation and a Lead Plaintiff Deadline of March 28, 2017

NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Pennsylvania on behalf of investors who purchased Egalet Corporation (NASDAQ:EGLT) securities between December 15, 2015 and January 9, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/egalet-corporation. There is no cost or obligation to you. The complaint alleges that, among other allegations, throughout the Class Period, Egalet made materially false and/or misleading statements concerning its lead product, ARYMO ER and the likelihood the product would receive oral abuse-deterrent labeling. If you suffered a loss in Egalet you have until March 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/egalet-corporation. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losses Suffered by Investors in Egalet Corporation

Sets Lead Plaintiff Deadline of March 28, 2017 -- EGLT

NEW YORK, March 17, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Egalet Corporation (“Egalet”) (NASDAQ:EGLT) between December 15, 2015 and January 9, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Mineff v. Egalet Corporation, et al. (Case No. 2:17-cv-00390-MMB) in the USDC for the Eastern District of Pennsylvania. Click here to view the complaint. To get more information go to: http://www.zlk.com/pslra/egalet-corporation or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that, among other allegations, throughout the Class Period, Egalet made materially false and/or misleading statements concerning its lead product, ARYMO ER and the likelihood the product would receive oral abuse-deterrent labeling. Take Action: if you suffered a loss in Egalet you have until March 28, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...
EGLT ALERT: Rosen Law Firm Reminds Egalet Corporation Investors of Important Deadline in Class Action – EGLT

NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Egalet Corporation securities (NASDAQ:EGLT) from December 15, 2015 through January 9, 2017, inclusive (the “Class Period”) of the important March 28, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Egalet investors under the federal securities laws. To join the Egalet class action, go to http://rosenlegal.com/cases-1046.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, throughout the Class Period Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Egalet’s business, operations, and prospects, including that: (1) Egalet misrepresented ARYMO ER’s oral abuse-deterrent profile, (2) Egalet falsely or misleadingly overstated ARYMO ER’s chances to receive the oral abuse-deterrent labeling, (3) the NDA for ARYMO ER lacked sufficient data to support the oral-labeling claims, (4) the label was likely not to include the oral abuse-deterrent claims, and (5) as a result, Egalet’s statements, as well as Defendants’ statements about Egalet’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 28, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1046.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

Read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Egalet Corporation of Class Action Lawsuit and Upcoming Deadline – EGLT

NEW YORK, March 03, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Egalet Corporation (“Egalet” or the “Company”) (NASDAQ:EGLT) and certain of its officers.  The class action, filed in United States District Court, Eastern District of Pennsylvania, is on behalf of a class consisting of investors who purchased or otherwise acquired Egalet securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934.
If you are a shareholder who purchased Egalet securities between December 15, 2015 and January 9, 2017, both dates inclusive, you have until March 28, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.  [Click here to join this class action] Egalet is a specialty pharmaceutical company developing, manufacturing and commercializing innovative treatments for pain and other conditions.  Egalet revolves around a proprietary technology called Guardian Technology (“Guardian”) which Egalet broadly applies for different classes of pharmaceuticals products.  Particularly, Egalet uses Guardian for its lead product ARYMO ER, an abuse deterrent oral morphine formulation for the management of severe pain requiring daily “around-the-clock” long-term opioid treatment. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) Egalet misrepresented ARYMO ER’s oral abuse-deterrent profile; (ii) Egalet falsely or misleadingly overstated ARYMO ER’s chances to receive the oral abuse-deterrent labeling; (iii) the Company’s New Drug Application for ARYMO ER lacked sufficient data to support the oral-labeling claims; (iv) the label was likely not to include the oral abuse-deterrent claims; and (v) as a result of the foregoing, Egalet’s public statements were materially false and misleading at all relevant times.  On January 9, 2017, post-market, Egalet issued a press release, filed on Form 8-K with the SEC, entitled “Egalet Receives FDA Approval for ARYMO™ ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated with Abuse-Deterrent Properties for Treatment of Chronic Pain,” announcing the approval of its product Arymo ER. The press release advised investors that the FDA had only granted an intravenous abuse-deterrent label claim and did not approve the oral abuse-deterrent labeling as requested by the Company.  On this news, Egalet’s share price declined $1.86, or 22.2%, to close at $6.52 per share on January 10, 2017. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 20.56
EGLT's PB Ratio is ranked lower than
95% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. EGLT: 20.56 )
Ranked among companies with meaningful PB Ratio only.
EGLT' s PB Ratio Range Over the Past 10 Years
Min: 1.41  Med: 3.43 Max: 41.56
Current: 20.56
1.41
41.56
PS Ratio 6.27
EGLT's PS Ratio is ranked higher than
61% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. EGLT: 6.27 )
Ranked among companies with meaningful PS Ratio only.
EGLT' s PS Ratio Range Over the Past 10 Years
Min: 3.5  Med: 40.19 Max: 670
Current: 6.27
3.5
670
EV-to-EBIT -1.58
EGLT's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. EGLT: -1.58 )
Ranked among companies with meaningful EV-to-EBIT only.
EGLT' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.7  Med: -2.3 Max: -0.3
Current: -1.58
-6.7
-0.3
EV-to-EBITDA -1.66
EGLT's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. EGLT: -1.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
EGLT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -6.9  Med: -2.4 Max: -0.3
Current: -1.66
-6.9
-0.3
Current Ratio 3.74
EGLT's Current Ratio is ranked lower than
53% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. EGLT: 3.74 )
Ranked among companies with meaningful Current Ratio only.
EGLT' s Current Ratio Range Over the Past 10 Years
Min: 0.17  Med: 3.02 Max: 7.42
Current: 3.74
0.17
7.42
Quick Ratio 3.67
EGLT's Quick Ratio is ranked lower than
51% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. EGLT: 3.67 )
Ranked among companies with meaningful Quick Ratio only.
EGLT' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 2.98 Max: 7.42
Current: 3.67
0.17
7.42
Days Inventory 177.57
EGLT's Days Inventory is ranked lower than
65% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. EGLT: 177.57 )
Ranked among companies with meaningful Days Inventory only.
EGLT' s Days Inventory Range Over the Past 10 Years
Min: 102.49  Med: 139.43 Max: 177.57
Current: 177.57
102.49
177.57
Days Sales Outstanding 23.84
EGLT's Days Sales Outstanding is ranked higher than
81% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. EGLT: 23.84 )
Ranked among companies with meaningful Days Sales Outstanding only.
EGLT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.72  Med: 56.56 Max: 321.28
Current: 23.84
4.72
321.28
Days Payable 238.55
EGLT's Days Payable is ranked higher than
85% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 58.37 vs. EGLT: 238.55 )
Ranked among companies with meaningful Days Payable only.
EGLT' s Days Payable Range Over the Past 10 Years
Min: 238.55  Med: 533.1 Max: 827.64
Current: 238.55
238.55
827.64

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -19.80
EGLT's 3-Year Average Share Buyback Ratio is ranked lower than
70% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. EGLT: -19.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
EGLT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -168.8  Med: -19.8 Max: 0
Current: -19.8
-168.8
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.16
EGLT's Price-to-Median-PS-Value is ranked higher than
93% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. EGLT: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
EGLT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.16  Med: 0.28 Max: 1.04
Current: 0.16
0.16
1.04
Earnings Yield (Greenblatt) % -63.00
EGLT's Earnings Yield (Greenblatt) % is ranked lower than
94% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. EGLT: -63.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
EGLT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2500  Med: 0 Max: 0
Current: -63
-2500
0

More Statistics

Revenue (TTM) (Mil) $16.96
EPS (TTM) $ -3.70
Beta0.53
Short Percentage of Float40.51%
52-Week Range $4.04 - 10.00
Shares Outstanding (Mil)25.21

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 39 60 85
EPS ($) -3.10 -2.40 -1.60
EPS without NRI ($) -3.10 -2.40 -1.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for EGLT

Headlines

Articles On GuruFocus.com
Egalet Announces U.S. Food and Drug Administration Acceptance of File for Prior Approval Supplement Apr 18 2017 
Egalet Corporation Announces Changes to Board of Directors Apr 10 2017 
Egalet to Participate in Spring Investor Conferences Apr 03 2017 
Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of Mater Mar 31 2017 
Egalet Deploys Salesforce to Begin Educating Healthcare Providers about ARYMO™ ER Mar 31 2017 
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet Mar 28 2017 
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Egalet Cor Mar 24 2017 
EGLT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving E Mar 21 2017 
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losse Mar 17 2017 
EGLT ALERT: Rosen Law Firm Reminds Egalet Corporation Investors of Important Deadline in Class Actio Mar 10 2017 

More From Other Websites
Egalet Announces U.S. Food and Drug Administration Acceptance of File for Prior Approval Supplement... Apr 18 2017
Egalet Corporation Announces Changes to Board of Directors Apr 10 2017
Egalet to Participate in Spring Investor Conferences Apr 03 2017
Egalet Deploys Salesforce to Begin Educating Healthcare Providers about ARYMO™ ER Mar 30 2017
The FDA News That Put The Wind Beneath Egalet Stock's Wings Mar 29 2017
Egalet Can Tout Abuse-Deterrent Opioid Painkiller Mar 29 2017
Egalet Corporation (Nasdaq: EGLT) to Ring The Nasdaq Stock Market Closing Bell Mar 29 2017
Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of... Mar 29 2017
DEADLINE TODAY: Levi & Korsinsky, LLP Reminds Shareholders it Has Filed a Complaint to Recover... Mar 28 2017
DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Egalet... Mar 28 2017
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Egalet... Mar 24 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Egalet... Mar 24 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover... Mar 24 2017
Blog Coverage Egalet Receives New US and International Patents for Guardian(TM) Technology Mar 24 2017
Egalet Gets 4 New Patents for Guardian Technology Mar 23 2017
Egalet Announces Issuance of New U.S. and International Patents for Guardian™ Technology Mar 23 2017
INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Egalet... Mar 21 2017
EGLT INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving... Mar 21 2017
Pain Therapeutics’ Remoxy ER Secures FDA Regulatory Guidance (PTIE,EGLT) Mar 21 2017
Nektar Pharma Opioid Drug Shows Promise In Phase 3 Mar 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)